Language: BG BG
← Back to results
By invitation only NCT05039866

Long-Term Follow-up of Subjects Who Were Treated With ST-920

Conditions: Fabry Disease Fabry Disease, Cardiac Variant

Sponsor: Sangamo Therapeutics

trial.available_in: БГ
Overview
Long-term follow-up of subjects who received ST-920 in a previous trial (ST-920-201) and completed at least 52 weeks post-infusion follow-up in their primary protocol. Enrolled subjects will be followed for a total of up to 5 years following ST-920 infusion.
Description
Non-interventional, multi-center, long-term follow-up (LTFU) study of subjects dosed with ST-920 in the clinical study ST-920-201. All subjects dosed in the study who completed at least 52 weeks post-infusion follow-up in their primary protocol will be offered to participate. Subjects who enroll will be monitored for a total of up to 5 years following ST-920 infusion.
Who can participate
Inclusion Criteria: * Subjects who received ST-920 therapy in a separate parent trial * Subjects who have consented to participate in this LTFU study. Exclusion Criteria: -This study has no exclusion criteria
Locations 5
Australia (1)
The Royal Melbourne Hospital
Parkville , Victoria
Canada (1)
M.A.G.I.C. Clinic Ltd.
Calgary , Alberta
Germany (1)
University Hospital of Würzburg
Würzburg
United Kingdom (1)
Addenbrooke's Hospital
Cambridge
United States (1)
University of California, Irvine
Irvine , California
Technical details
Status
By invitation only
Study type
OBSERVATIONAL
Sex
Male and female
Minimum age
18 Years
Healthy volunteers
No
Start date
16.08.2021
Completion date
01.03.2039
Registry ID
NCT05039866
Source
anzctr
trial.inquiry_btn

Information is automatically extracted from ClinicalTrials.gov. Consult your doctor before taking action.